Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
McKinsey
Johnson and Johnson
Mallinckrodt
Dow

Last Updated: May 19, 2022

Investigational Drug Information for Nimotuzumab


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Nimotuzumab?

Nimotuzumab is an investigational drug.

There have been 89 clinical trials for Nimotuzumab. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2015.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Squamous Cell, and Esophageal Neoplasms. The leading clinical trial sponsors are Biotech Pharmaceutical Co., Ltd., Sun Yat-sen University, and Chinese Academy of Medical Sciences.

There are eighty-six US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Nimotuzumab
TitleSponsorPhase
Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCCXijing HospitalPhase 2
Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine NeoplasmsFudan UniversityPhase 2
Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell CarcinomaThe First Affiliated Hospital of Zhengzhou UniversityPhase 2

See all Nimotuzumab clinical trials

Clinical Trial Summary for Nimotuzumab

Top disease conditions for Nimotuzumab
Top clinical trial sponsors for Nimotuzumab

See all Nimotuzumab clinical trials

US Patents for Nimotuzumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Nimotuzumab See Plans and Pricing Binding molecules specific for HER3 and uses thereof MEDIMMUNE, LLC (Gaithersburg, MD) See Plans and Pricing
Nimotuzumab See Plans and Pricing Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL) See Plans and Pricing
Nimotuzumab See Plans and Pricing Anti-EGFR activatable antibodies CytomX Therapeutics, Inc. (South San Francisco, CA) See Plans and Pricing
Nimotuzumab See Plans and Pricing Substituted urea derivatives and pharmaceutical uses thereof SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Nimotuzumab

Drugname Country Document Number Estimated Expiration Related US Patent
Nimotuzumab Australia AU2012340766 2031-11-23 See Plans and Pricing
Nimotuzumab Brazil BR112014012539 2031-11-23 See Plans and Pricing
Nimotuzumab Canada CA2856297 2031-11-23 See Plans and Pricing
Nimotuzumab China CN104093743 2031-11-23 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
McKinsey
Johnson and Johnson
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.